Medicago

Vaccine Research + Production Facility

Medicago’s facility is designed to research and produce plant-based commercial-grade vaccines. It includes a 27,000 sf fully automated greenhouse and headhouse, as well as extensive laboratory, production and office space. This revolutionary hybrid facility represents the intersection of some of the most advanced science in biotechnology and pharmaceutical vaccine research and production. The greenhouse has a plant capacity of 90,000 plants and incorporates customized robotics and infiltration equipment. A state-of-the-art extraction and purification unit was also installed. Construction included Class A (1,000), B (10,000) and C (100,000) modular clean rooms. The project received substantial federal funding from the Defense Advanced Research Projects Agency (DARPA) to demonstrate the scalable manufacturing of its plant-expressed Virus-Like Particle (VLP) vaccines.

“BE&K Building Group was a team player throughout the project. They worked diligently and safely to keep the project on schedule and meet project milestones as dictated by our agreement with DARPA. Our experience with BE&K Building Group was outstanding. They did an incredible job delivering our technically complex, 97,000 sf facility in just twelve months’ time.”
— Mike Wanner, Executive Vice President of Operations, Medicago

  • Service — Design-Build
  • Architect — Clark Nexsen
  • Developer — Alexandria Real Estate Equities
  • Multiple Award-Winning
  • Designed and built in less than 12 months